Advances in breast cancer research are ongoing. According to research, subtypes of breast cancer determines the treatment options. These three main breast cancer subtypes respond differently to various treatments:
1. HR positive– For this type of breast cancer, targeted therapy uses drugs or other substances to attack cancer cells with less harm to normal cells. There is a new focus on adding targeted therapies to hormone therapy for advanced or metastatic HR-positive breast cancer. These treatments could prolong the time until chemotherapy is needed and ideally, extend survival.
2. HER2 Positive– This type ofmetastatic breast cancer is more likely to spread to the brain than other types of breast cancer. HER2-targeted drugs that can cross the blood-brain barrier are being studied for the treatment and prevention of brain metastases. In 2020, the FDA approved the use of the drug tucatinib (Tukysa) combined with trastuzumab and capecitabine (Xeloda) for HER2-positive breast cancer that either can’t be removed with surgery or has spread to other parts of the body. In one study, women who received tucatinib in addition to the other two drugs lived longer both without their disease progressing and overall than women receiving only trastuzumab and capecitabine. This includes women whose cancer had spread to the brain.
3. Triple-Negative– This type of breast cancers (TNBC)are the hardest to treat because they lack both hormone receptors and HER2 overexpression, so they do not respond to therapies directed at these targets. Therefore, chemotherapy is the mainstay for treatment of TNBC. Some treatments now being used are:
The following are some of the latest news articles on breast cancer research and study updates:
View the full list of Breast Cancer Research Results and Study Updates.
Source: National Cancer Institute https://www.cancer.gov/types/breast/research